Enzo Biochem — Proxy Contest (January 2020)
71 slides from Enzo Biochem's proxy contest presentation, Jan 8, 2020
Slide 1: Harbert Discovery Fund Releases Detailed Investor Presentation on Enzo Biochem
ren Harbert Management ei@) Corporation Harbert Discovery Fund Releases Detailed Investor Presentation Highlighting Case for Change at Enzo Biochem Puts Spotlight on Decades of Enzo’s False Promises and Underperformance While its Board and Management Continue to Receive Excessive Compensation at Sha
Slide 2: Vote on the BLUE Proxy Card to Cure Enzo Today
ren Harbert Management ei@) Corporation VOTE ON THE BLUE PROXY CARD TO CURE ENZO TODAY Important Information about Participants in a Proxy Solicitation: Harbert Discovery Fund, LP (“Harbert Discovery’), Harbert Discovery Fund GP, LLC (“Harbert Discovery GP”), Harbert Discovery Co-Investment Fund |,
Slide 3: ren Harbert
ren Harbert Management BI@ Corporation Dan Zacchei / Sarah Braunstein, 212-486-9500 dzacchei@sloanepr.com/sbraunstein@sloanepr.com
Slide 4: Enzo Biochem: The Case for Change
in mimi Harbert Management Corporation Enzo Biochem: The Case for Change January 7, 2020
Slide 5: Important Information
Important Information This presentation, the materials contained herein, and the views expressed herein (this Presentation”) are for discussion and general informational purposes only. This Presentation does not have regard to the specific investment objective, financial situation, suitabilty, or th
Slide 6: Table of Contents
Table of Contents |, Executive Summary ll. Enzo: The Case for Change a Sustained History of Value Destruction 0 History of Overpromising and Underdelivering () Failed Corporate Governance Q Excessive Compensation for Underperformance Ill. HDF's Independent Nominees lV. Enzo: The Opportunity
Slide 7: I. Executive Summary
I. EXECUTIVE SUMMARY SEESE NG, ) < WEES et y VA ;
Slide 8: Enzo Biochem
Enzo Biochem er) Ticker: ENZ (NYSE) Market Cap: $133.6 million * Founding Year: 1976 * Headquarters: Farmingdale, NY « Founders: « Elazar Rabbani « Barry Weiner * Shahram Rabbani Source: Bloomberg, compary flings Enzo runs clinical labs in the Northeast region, develops platforms and reagents for us
Slide 9: Harbert Discovery Fund and Harbert Management Corporation
Harbert Discovery Fund and Harbert Management Corporation = 7 illu, Harbert Management FIM @ Corporation Harbert Discovery Fund (“HDF”) HDF currently owns approximately 11.8% of the outstanding shares of Enzo, making it the Company's largest shareholder * HDF invests in a concentrated portfolio of p
Slide 10: Executive Summary
Executive Summary : = « The Company has underperformed the Russell 2000 by nearly 1,250% over the last 30 years - with a pattern of value destruction across nearly every relevant time period (1, 3, 5, 10, 30-year) and index / peer group Enzo has overpromised (2019 proxy peers, Russell 2000 Index, et
Slide 11: Performance Against Peers Highlights Value Destruction
Performance Against Peers Highlights Value Destruction Common shareholders have suffered decades of stock price and financial underperformance 4972% 1,612% 1,251% 511% A 334% 253% 21% 974 y y y 12018 146 oy, 1 6 15% | mm 66%. 4y | (14%) (42%) (499) (61%) 1 Year TSR 3 Year TSR 5 Year TSR 10 Year TSR
Slide 12: Enzo's Compensation
Enzo’s Compensation Committee sets compensation levels based on much larger peer companies, failing to account for Enzo's smaller size $1 500 $1200 $900 $600 $300 | OPPROne | 210 2012012 2013-2014 ONS NT aoe 2019 NENZ Proxy Peer Group Median ay CEO an C of Ma zation 20% ; | | | | | 0.0% | | 200 2011
Slide 13: Fresh Perspectives in the Boardroom are Urgently Needed
Fresh Perspectives in the Boardroom are Urgently Needed = “= Directors HDF is Seeking to Remove Independent Directors HDF is Seeking to Add Barry W. Weiner, Age 69 Am, Fabian Blank, Age 45 Re) Executive Experience: Board Experience: Director Tenure: : (> Meduna Klinik Group Georgia Healthcare 10-Yea
Slide 14: Growth / Value Perspective, Governance, Strategic Guidance
Growth / Value Perspective Governance Strategic Guidance
Slide 15: II. Enzo: The Case for Change
II. ENZO: THE CASE FOR CHANGE
Slide 16: Enzo: The Case for Change
Enzo: The Case for C CHANGE I$ NEEDED HE FACT o Common shareholders have suffered years of stock price and financial underperform ance - . ; excluding legal settlements, the Company has not produced one dollar of operating profits | Sustained History of Value since 2004. Destruction o Poor performan
Slide 17: Enzo: The Case for Change
Enzo: The Case for C CHANGE I$ NEEDED HE FACT o Common shareholders have suffered years of stock price and financial underperformance - | : excluding legal settlements, the Company has not produced one dollar of operating profits | Sustained History of Value since 2004. Destruction o Poor performanc
Slide 18: Poor Stock Price Performance
Poor Stock Price Performance Enzo’s management team and Board have consistently destroyed shareholder value. Excluding legal settlements, the company has not produced one dollar of operating profits since 2004. Over the last ten years, the stock price is down -49% with -6.5% annualized returns an Fi
Slide 19: Performance Against Peers Highlights Value Destruction
Performance Against Peers Highlights Value Destruction Common shareholders have suffered decades of stock price and financial underperformance 4972% 1,612% 1,251% 511% A 334% 253% 21% 974 y y y 12018 146 oy, 1 6 15% | mm 66%. 4y | (14%) (42%) (499) (61%) 1 Year TSR 3 Year TSR 5 Year TSR 10 Year TSR
Slide 20: Missteps Translating into Loss of Value
Missteps Translating into Loss of Value ss Enzo has drastically underperformed over any time period and any relevant peer group / index 1 Year TSR 3 Year TSR 50.0% 100.0% 50.0% 25.0% 0.0% 0.0% -50.0% -25.0% -100.0% Nov-2018 Jan-2019 Mar-2019 May-2019 Jub2019 Sep-2019 Nov-2016 Nov-2017 Nov-2018 5 Yea
Slide 21: Poor Capital Allocation
Poor Capital Allocation moo oA ns The long-term underperformance is a result of weak governance, misaligned incentives, poor capital allocation and a misguided operational strategy. Enzo has spent nearly $276 million on capital investments, R&D, legal expenses and M&A since 2004 which is over two ti
Slide 22: Poor returns on capital, assets and equity
ane ne on eel BS va id é Rs Enzo’s capital allocation strategy has delivered extremely poor returns on capital, assets and equity which has led to massive shareholder value destruction. Management appears to be et abiteiOus of the mele of sat pear investment Raclsions. ‘| at bee pect ideal f fe i (a
Slide 23: Enzo: The Case for Change
Enzo: The Case for C CHANGE I$ NEEDED HE FACT o Common shareholders have suffered years of stock price and financial underperform ance - . ; excluding legal settlements, the Company has not produced one dollar of operating profits | Sustained History of Value since 2004. Destruction o Poor performan
Slide 24: AmpiProbe: The Promises
AmpiProbe: The Promises 204 2 Introduction to AmpiProbe and its significant potential: “In addition, we have made sut DI on the first assay based on AmpiProbe, our intemally- designed proprietary technology which can enable one to perform realtime PCR type amplification, or DNA amplification and det
Slide 25: AmpiProbe: The Results
AmpiProbe: The Results The Reality Today Despite its statements over the past seven years that AmpiProbe would drive growth and profitability for Enzo, AmpiProbe has not generated any material revenue for the Company. * AmpiProbe has received approval in the state of New York, but has yet to receive
Slide 26: Strategic Partnerships: The Promises
Strategic Partnerships: The FTES ie me 6 Ws For years, management has repeatedly pointed to strategic partnerships as a source of growth and profitability “Establishing business relationships on many fronts is a key goal of the many goals that we have set forth for our team here. We are in dialog wi
Slide 27: Strategic Partnerships: The Results
Strategic Partnerships: The Results The Reality Today Five years later, no deal has ever been completed - and only vague details of discussions or potential partners have been presented publicly to shareholders Has Enzo made any meaningful effort to consummate a partnership that could provide growth
Slide 28: Management Claims Versus the Results
Management Claims Versus the Results thre = ES For years, Barry Weiner has consistently made comments that Enzo was on the cusp of creating substantial shareholder value. Yet, shareholders have only losses to show for these misleading comments which have come during a remarkable period of equity mar
Slide 29: Reactive Behavior
Reactive Behavior ae * Westated in our September 2019 public letter to shareholders that Enzo should explore strategic alternatives for the Therapeutics business. * |n response, management said that we do not understand the Company and do not know what we are doing. «Yet in response to our call for
Slide 30: Enzo's Delivery Pipeline Delay: No End in Sight
Enzo’s Delivery Pipeline Delay: No End in Sight ENZ Development Activity from 10-K Exoected Availabilitvas of 2017 10-K 2018 10-K 2016 10-K 201910-K — Platform ANPIPROBE® REAL-TIME ANPLIFICATION AND DETECTION HIV Viral Load HPV High Risk Screen ANPIPROBE@REAL-TIME AIVPLIFICATION AND DETECTION HSVIVZ
Slide 31: Enzo: The Case for Change
Enzo: The Case for C CHANGE I$ NEEDED HE FACT o Common shareholders have suffered years of stock price and financial underperform ance - . ; excluding legal settlements, the Company has not produced one dollar of operating profits | Sustained History of Value since 2004. Destruction o Poor performan
Slide 32: Corporate governance assessment
makvs Essential Characteristics Comments Independence and Accountability + Outdated governance structure. + Combined CEO and Chairman Role. + Classified Board. Checks and Balances + Conflicts of interest. + CEO/ Chairman tenured for 44 years. + Fomer CFO /Current Board member tenured for 43 years. R
Slide 33: Change is Desperately Needed
Change is Desperately Needed The Board is entrenched with Directors who have overseen significant value destruction at Enzo Barry W. Weiner Director since 1972 Co-Founder, President, Principal Accounting Officer, Treasurer Over tenured - Mr. Weiner has served on the Board for 43 years and as Preside
Slide 34: Family Affairs at Enzo
Family Affairs at Enzo ae Mindset at Enzo Related Party Transactions Demonstrate the « Enzo Labs has leased a facility in Farmingdale, New York, from Pari Management since 1989. ¢ Pari Management Corporation is owned equally by Dr. Elazar Rabbani, Barry Weiner (and his wife), and former officer and
Slide 35: Brothers-in-Law
Brothers-in-Law Farmingdale, NY Facility
Slide 36: Enzo's Employee Reviews
Enzo’s Employee Reviews Corporate governance issues in the boardroom affect the Company culture as a whole glassdoor ir glassdoor r glassdoor r glassdoor Disorganized Family Environment tis a small company that is family orientated with stresstul job assignments. Upper management is highly disorgani
Slide 37: Family Feud in the Boardroom
Family Feud in the Boardroom Law36 Enzo Settles Litigation With Founder Over Firing By Christopher Norton Law360 (Janyary 28, 2020, 4:14 PIV EST) ~ Enzo Biochem Inc, has MarketWatch Enzo Biochem Shares Fall Day Before Co-Founder’s Proxy Fight Enzo co-founder Shahram K. Rabbani was fired from the Com
Slide 38: Family Feud in the Boardroom
Family Feud in the Boardroom FE i 2 ay A OE Enzo is Run Like a “Family Business” In his preliminary proxy statement, Mr. Shahram Rabbani highlighted the myriad operational, corporate governance, and interpersonal issues still facing Enzo: Preliminary Proxy Statement “The board of directors has allow
Slide 39: Lone Star Value
Lone Star Value e e Lins = 12 Aes = 3, _% In 2015, Lone Star Value wrote a letter to shareholders making a case for change at Enzo and nominating two directors to the Board. Lone Star Value raised concerns about the Company's chronic underperformance and corporate governance failings - many of which
Slide 40: Enzo's Response to Lone Star was the Same as its Response to HDF Today
Enzo’s Response to Lone Star was the Same as its Response to HDF Today The Time for “NOW” was in 2015 and five years later Enzo has little to show for it Change is.... What makes this time any different? Ps) . Enzo Und PP PPP SUMMARY. vet eyte corpany ur cay potions Eno on -term value for Rs stort 1
Slide 41: No Successful Changes Have Been Made
No Successful Changes Have Been Made Eno Y Executing on a corporate strategy which has to thrive in the challenging MDx marketplace = = 2 = S & ae = s a IS as i= = is = Is a is = es iS = TSR of 86.0% ¥ Rapidly improving financial performance, inc| pipeline Y Efficiently harvesting valuable IP estate
Slide 42: Shareholders are Frustrated
holders are Frustrated ae On Enzo’s Q1 2020 earnings call in December 2019, a shareholder highlighted management's history of value destruction and called out its failure to deliver on promises éé Hi Barry. I've E yeal E ] | recently bought the stock because of Enzo's therapeutic programs. The more
Slide 43: Harbert has tried to engage constructively with Enzo
Harbert has 22> i. tried fo engage constructively with Enzo SS Oct. 22, 2048 Nov. 15, 2018 Dec. 18, 2048 March 27, 2019 May 7, 2019 May 28, 2049 June 13, 2019 June 24,2019 June 25, 2019 June 26, 2019 July 8, 2019 July 10, 2019 July 12, 2019 Harbert Discovery Representatives called the Company's Pres
Slide 44: Timeline of engagement continued
July 25, 2019 July 30, 2019 Sept. 17, 2019 Oct. 6, 2019 Oct. 9, 2019 Oct. 10, 2019 Oct. 14, 2019 Oct. 16, 2019 Oct. 18, 2049 Nov. 14, 2019 Nov. 15, 2019 Dec. 2, 2019 Mr. Lucas responded to Mr. Hanna’s July 12 email, copying Mr. Weiner. Mr. Lucas expressed disappointment in the Board’s rejection of t
Slide 45: For months, HDF has attempted to engage in productive dialogue
For months, HDF has attempted to engage in productive dialogue with the Company to reconstruct the Board. The Company's response of hiding behind lawyers and refusing to seriously engage at a business level has been unproductive and discouraging, highlighting the deep-seated issues resulting from th
Slide 46: Enzo: The Case for Change
Enzo: The Case for C CHANGE I$ NEEDED HE FACT o Common shareholders have suffered years of stock price and financial underperform ance - . ; excluding legal settlements, the Company has not produced one dollar of operating profits | Sustained History of Value since 2004. Destruction o Poor performan
Slide 47: Excessive Compensation for Underperformance
Excessive Compensation for Underperformance Enzo has reported operating losses every year since 2004 Yet, the Board approved paying the Dr. Rabbani and Mr. Weiner over $34 million, including a significant cash bonus, every single year |Dr. Rabbani and Mr. Weiner Cumulative Compensation m Cumulative
Slide 48: Excessive Compensation for Underperformance
Excessive Compensation for Underperformance Lists = a In our view, Enzo’s underperformance is a direct result of weak governance and misaligned incentives Tand Mr Wainer land Wir weiner = S s 2 & 2 8 g $40 Source: Bloomberg, compary flings
Slide 49: Questionable Compensation Practices
Questionable Compensation Practices The Board appears to be using unjustifiable and inaccurate financial results when deciding management’s 2019 compensation * 50% bonus threshold met with a 20.6% decline in revenue. Management should not be compensated for a drastic decline in revenue. * Inits prox
Slide 50: Management Compensation has been Inflated
Management Compensation has been Inflated as 13 The Board’s decision to use a peer set of much larger companies appears to be a clear attempt to inflate management's egregious take- home pay even in the face of horrible fundamental performance Market Cap ($ in millions) Compensation as % of Market C
Slide 51: Enzo's Compensation
Enzo’s Compensation Committee sets compensation levels based on much larger peer companies, failing to account for Enzo's smaller size $1 500 $1200 $900 $600 $300 | OPPROne | 210 2012012 2013-2014 ONS NT aoe 2019 NENZ Proxy Peer Group Median ay CEO an C of Ma zation 20% ; | | | | | 0.0% | | 200 2011
Slide 52: III. HDF's Independent Nominees
II]. HDF's INDEPENDENT NOMINEES
Slide 53: Our Independent Nominees are the Right Fit
Our Independent Nominees are the Right Fit Fabian Blank Mr. Blank brings extensive experience and expertise across all sectors of the healthcare industry, as well as a business and investment background through his roles advising healthcare executives and boards. Extensive Healthcare Experience Busi
Slide 54: Our Independent Nominees are the Right Fit
Our Independent Nominees are the Right Fit Peter J. Clemens, IV ive in the healthcare inlasny a seniacadvibons and strategist Mr. Clemens brings experience as an exec: to healthcare profes cross a plethora of medical industries and an extensive background in and knowledge of hea Financial Expertise
Slide 55: Growth / Value Perspective, Governance, Strategic Guidance
Growth / Value Perspective Governance Strategic Guidance
Slide 56: IV. Enzo: The Opportunity
IV. ENZO: THE OPPORTUNITY
Slide 57: Despite decades of poor oversight and mismanagement
Despite decades of poor oversight and mismanagement, Enzo has a collection of businesses and assets that, with a sound growth strategy, more prudent expense structure, appropriate capital allocation, and effective, independent oversight, could see significant improvement and create substantial value
Slide 58: Our Plan to Create Shareholder Value
Our Plan to Create Shareholder Value ; Sr =" Establish New Corporate Strategy
Slide 59: New Corporate Strategy
New Corporate Strategy Clinical Services Peers: | * Enzo should focus on the inherent strengths of its lab’s location in a high-density population market and strong relationships with existing customers. Building on those two strengths coupled with prudent cost cuts could return that segment to prof
Slide 60: Our Candidates Have Already Positively Impacted Enzo
Our Candidates Have Already Positively Impacted Enzo i rs (2 ESS ee Since we first highlighted Enzo’s numerous deficiencies and requested changes to the Board to create long-term shareholder value Enzo has: Y¥ Engaged Lazard to assist in strategic relationship exploration. ¥ Committed to a strategic
Slide 61: Immediate, Near-Term and Long-Term Action Items
Immediate Action Items Near-Term && Address Management Compensation: Align management compensation with shareholders. Target Bloated Cost Structure: Right size the operating expense base to put Enzo ona path to profitability. Evaluate Planning and Budgeting Process: Review budgeting and forecasting
Slide 62: Align Management Compensation
Align Management Compensation Incentives Matter Action Item y Enzo’s historical poor performance is a direct result of management being rewarded for that performance. y Even though Enzo has not generated an operating profit since 2004, w management was paid bonuses every year as well as given consis
Slide 63: Address Excess Costs
Address Excess Costs Enzo has a bloated cost structure Immediate x Enzo’s Madison Avenue headquarters are excessive for a business of this size. Action Item x The Company has spent $36 million on Therapeutics R&D since 2004 with not one dollar of revenue to show for it x Legal expenses have ranged f
Slide 64: Evaluate Planning and Forecasting Processes
Evaluate Planning and Forecasting Processes Immediate Enzo’s consistent failure to deliver on its potential is reflective Action Item of inadequate budgeting and forecasting processes x tis clear that Enzo does not have the appropriate systems and processes in place to accurately forecast the busine
Slide 65: Deliver on the Potential of Partnerships
Deliver on the Potential of Partnerships Enzo has failed to deliver on the potential of partnerships to drive growth: Action Item x Enzo has highlighted the potential of partnerships for years in an effort to commercialize its products and technologies. But the Company has failed to deliver. Growth
Slide 66: New Corporate Strategy
New Corporate Strategy 7 rey = Enzo’s current strategy does not position the Company for (Vv) success x Enzo has neither the seale nor the expertise to executive on the goal of “creating a new paradigm for the laboratory and diagnostic marketplaces.” x Attempting to do so puts the whole enterprise a
Slide 67: Explore Sale of Non-Core Assets
Explore Sale of Non-Core Assets ae Enzo’s value can be realized through a series of strategic monetization efforts x Enzo has a very valuable patent portfolio of 406 patents and 75 patents pending as evidenced by $117 million of settlements since 2001.! x Unfortunately, Enzo's legal expenses over th
Slide 68: Return Excess Cash and Deliver Profitable Growth
Return BUCS Cash and Deliver PraMlas Sra There is real opportunity to be realized at Enzo: Y Following the right sizing of the Clinical Services cost structure, accelerated growth in the Life Sciences division, the sale of non-core IP, and the sale of the Therapeutics division. Enzo could have a cas
Slide 69: Fresh perspective in the boardroom will hold management accountable
Fresh perspective in the boardroom will hold management accountable, forcing them to stop value destroying activities, while refocusing the Company on its most promising areas in order to drive profitable growth in the long term.
Slide 70: Vote on the BLUE Proxy Card to Protect and Grow Your Investment in Enzo
Vote on the BLUE Proxy Card to Protect and Grow Your Investment in Enzo | Our highly-qualified independent director nominees will truly represent and act in the best interests of all shareholders. JV They will work to realign the Company's operating and growth strategy and create significant value a
Slide 71: Contact Information
Contact Information Shareholders If you have any questions, or need assistance voting your BLUE proxy card, please contact: PARTNERS 1212 Avenue of the Americas, 24th Floor New York, NY 10036 Telephone for Banks, Brokers, and International Shareholders: +1 212-297-0720 Shareholders may call toll-fre